Debiopharm‘s portfolio company Carevive has announced that it has completed its Series C fundraising with Qure Ventures joining Philips Health Technology Ventures, Debiopharm, and the existing investors to complete the round. This comes hard on the heels of the good news of the appointment of industry veteran Bruno Lempernesse as CEO. The funds will be used to advance Carevive’s patient-centered mission to improve the way cancer care is delivered.
Access their full press release here